Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 12Gynecologic 5Gastrointestinal 5Genitourinary 4Dermatologic 4Breast 3Sarcoma 2Other solid neoplasm 2Head & Neck 2Plasma cell 1CNS 1

Conditions

Head and Neck Neoplasms 13Squamous Cell Carcinoma of Head and Neck 8Uterine Cervical Neoplasms 7Anus Neoplasms 7Ovarian Neoplasms 6Nasopharyngeal Carcinoma 6Melanoma 6Vaginal Neoplasms 5Stomach Neoplasms 5Penile Neoplasms 5Oropharyngeal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neoplasm Metastasis 4Esophageal Neoplasms 4Vulvar Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Lung Neoplasms 2Hodgkin Disease 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 29Paclitaxel 7Magnetic Resonance Spectroscopy 7Cisplatin 7Pemetrexed 6Docetaxel 6Carboplatin 6Radiotherapy 5Nivolumab 5Drug Therapy 5Standard of Care 4Specimen Handling 4Gemcitabine 4Cetuximab 4Blood Specimen Collection 4epacadostat 3X-Rays 3Surveys and Questionnaires 3Oncolytic Virotherapy 3Nicotine 3Fluorouracil 3Filgrastim 3Cyclophosphamide 3Bupropion 3Bortezomib 3Biopsy 3spartalizumab 2selpercatinib 2sargramostim 2pralsetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × fludarabine × Head & Neck × Clear all
NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
15 enrolled
DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT05069935 2023-09-21

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
16 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡